Compare MNSO & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MNSO | EWTX |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.7B |
| IPO Year | 2020 | 2021 |
| Metric | MNSO | EWTX |
|---|---|---|
| Price | $9.23 | $43.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $26.20 | ★ $39.00 |
| AVG Volume (30 Days) | ★ 967.4K | 941.9K |
| Earning Date | 05-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.58% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.09 | N/A |
| Revenue Next Year | $15.43 | N/A |
| P/E Ratio | $20.04 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.21 | $13.69 |
| 52 Week High | $25.55 | $48.40 |
| Indicator | MNSO | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 26.74 | 52.41 |
| Support Level | $9.21 | $41.31 |
| Resistance Level | $13.24 | $45.48 |
| Average True Range (ATR) | 0.25 | 2.04 |
| MACD | -0.12 | -0.18 |
| Stochastic Oscillator | 4.03 | 50.00 |
MINISO Group Holding Ltd is a value retailer offering a variety of trendy lifestyle products featuring IP design. The principal activity of the Company is investment holding. The company's product categories include home decor, small electronics, textiles, accessories, beauty tools, toys, cosmetics, personal care, snacks, fragrance and perfumes, and stationery and gifts. Its segment includes the MINISO brand -Chinese Mainland and MINISO brand-Overseas which is engaged in the Design, buying, and sale of lifestyle products, and the TOP TOY brand, which is engaged in the Design, buying, and sale of pop toys. The company generates maximum revenue from theMINISO brand -Chinese Mainland segment. Geographically, it derives a majority of its revenue from Chinese Mainland.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.